Sean A. Grimm

Oncology
4405 Weaver Pkwy
Warrenville, IL 60555

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications

Phase 1 evaluation of patients with newly diagnosed glioblastoma treated with radiation, nivolumab, and IDO1 enzyme inhibitor BMS-986205.

Phase 1 evaluation of patients with newly diagnosed glioblastoma treated with radiation, nivolumab, and IDO1 enzyme inhibitor BMS-986205.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 24, 2026

Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205.

Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205.

Journal: Research square
Published: October 03, 2025

A Phase II Trial of Bevacizumab in Patients with Recurrent/Progressive Solid Tumor Brain Metastases That Have Progressed Following Whole-Brain Radiation Therapy.

A Phase II Trial of Bevacizumab in Patients with Recurrent/Progressive Solid Tumor Brain Metastases That Have Progressed Following Whole-Brain Radiation Therapy.

Journal: Cancers
Published: April 30, 2024

A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma.

A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma.

Journal: Neuro-oncology advances
Published: October 13, 2022

A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics.

A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics.

Journal: Neuro-oncology
Published: August 10, 2022

Secondary CNS myeloma with remission after systemic CNS-penetrating agents.

Secondary CNS myeloma with remission after systemic CNS-penetrating agents.

Journal: Neuro-oncology advances
Published: July 27, 2022

A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.

A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.

Journal: Journal of neuro-oncology
Published: August 12, 2021

Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.

Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.

Journal: The Lancet. Oncology
Published: February 18, 2021

Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.

Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.

Journal: Neuro-oncology
Published: November 12, 2019

Using methylation profiling to diagnose systemic metastases of pleomorphic xanthoastrocytoma.

Using methylation profiling to diagnose systemic metastases of pleomorphic xanthoastrocytoma.

Journal: Neuro-oncology advances
Published: August 11, 2019

Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report.

Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report.

Journal: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
Published: February 24, 2019

Prognosis of older patients with low-grade glioma: A retrospective study.

Prognosis of older patients with low-grade glioma: A retrospective study.

Journal: Integrative cancer science and therapeutics
Published: October 01, 2017
Showing 1-12 of 35

Last Updated: 09/26/2026